SELLAS Life Sciences Group, Inc.
corporate_fare Company Profile
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for SLS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 10 rated 8 or above. Recent SEC coverage for SLS spans 10-Q, 8-K.
Recent high-impact activity:
- Sellas Prices $150M Offering at $13, a 28% Discount to Tuesday's Close
- Cancer Vaccine Data Sends Shares Up 156%, Then $150M Offering Cools the Rally
- $150M Equity Offering Launched Days After REGAL Trial Win
- SELLAS Triples as Cancer Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial
- Phase 3 REGAL Win: Cancer Vaccine Cuts Death Risk 41% in AML, Median Survival 24.0 vs 14.7 Months
Financial Snapshot
Short Interest & Short Volume
6.70 days to coverFINRA reported short interest of 57,126,298 shares in SLS as of the October 30, 2026 settlement, a 6.3% increase from the prior period — about 6.7 days to cover at its recent average daily volume. On November 20, 2026, 57.1% of SLS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SLS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-19.
Final Terms of $150M Offering · Net Proceeds and Fees
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →